arrow
F

Franco Folli

health sciences
H指数:71
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Synergic effect of diet and polysaccharide-based complex administration in the treatment of children and adolescents with metabolically unhealthy obesity: the Polymets Study

饮食与多糖复合物给药在治疗代谢不健康肥胖儿童及青少年中的协同效应:Polymets 研究

2026-03-140
OAAI
Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis: An Exploratory Post Hoc Analysis From a Phase 3 Randomized Controlled Trial

Esmethadone (REL-1017) 在伴有抗抑郁药快速耐受性的重度抑郁症患者中的探索性事后分析:一项来自3期随机对照试验的研究

2025-12-010
PRE
Analysis of morbid obese diabetic and non-diabetic patients: clinical and social characteristics, habits and workup to undergo bariatric surgery in Lombardy, Italy

对病态肥胖的糖尿病患者和非糖尿病患者的分析:伦巴第地区(意大利)的临床和社会特征、习惯以及接受减肥手术的评估流程

2025-11-120
OAAI
Continuous interstitial glucose monitoring in diabetic and non-diabetic critically ill patients is simple and accurate: comparison with venous, arterial and capillary glucose measurements

连续性组织间液葡萄糖监测在糖尿病和非糖尿病危重症患者中的应用简单且准确:与静脉、动脉和毛细血管葡萄糖测量的比较

2025-06-070
OA
Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study

在真实世界环境中,对于接受SGLT2抑制剂治疗的、肥胖且具有高风险心血管疾病的2型糖尿病患者,添加Dulaglutide可改善其血糖和体重控制。AWARE-2研究

2025-02-010
OAAI
Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule

胰高血糖素样肽1受体是一种T细胞阴性共刺激分子

2024-06-0113
PRE
Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide

达格列净联合口服司美格鲁肽实现2型糖尿病的药物性缓解

2024-01-017
OAAI
The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users
2023-06-077
OAAI